merged_alzheimers-treatment-kisunla-donanemab.txt
<other>Answers based solely on the provided article.</other>
<question_number>1</question_number>
<answer>Significant safety risks (brain swelling and bleeding) combined with only modest clinical benefit</answer>
<question_number>2</question_number>
<answer>It may discourage patients from joining other clinical trials and slow overall progress in developing better treatments</answer>
<question_number>3</question_number>
<answer>He said there is no correlation in studies between removal of amyloid plaques and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>It could raise concerns about Kisunla's safety by indicating a greater risk of brain swelling and bleeding</answer>
<question_number>5</question_number>
<answer>Lilly says the higher price reflects that patients can stop Kisunla after amyloid is cleared, reducing long-term cost, inconvenience and risk</answer>
<question_number>6</question_number>
<answer>Emphasis on anti-amyloid drugs might discourage patients from participating in other clinical trials</answer>
<question_number>7</question_number>
<answer>Monthly dosing and the possibility of stopping treatment after plaques are cleared reduce treatment frequency and overall inconvenience</answer>
<question_number>8</question_number>
<answer>Amyloid (amyloid plaques)</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Participants with intermediate tau levels declined more slowly than those with high tau, suggesting earlier (lower-tau) treatment is more effective</answer>